MA34711B1 - Polypeptides se liant aux recepteurs de chimiokines - Google Patents

Polypeptides se liant aux recepteurs de chimiokines

Info

Publication number
MA34711B1
MA34711B1 MA35963A MA35963A MA34711B1 MA 34711 B1 MA34711 B1 MA 34711B1 MA 35963 A MA35963 A MA 35963A MA 35963 A MA35963 A MA 35963A MA 34711 B1 MA34711 B1 MA 34711B1
Authority
MA
Morocco
Prior art keywords
polypeptides
cxcr2
chemokine receptors
polypeptides binding
relates
Prior art date
Application number
MA35963A
Other languages
English (en)
Inventor
Michelle Bradley
Zarin Brown
Steven John Charlton
Karen Cromie
Bruno Dombrecht
Soren Steffensen
Heeke Gino Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34711B1 publication Critical patent/MA34711B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des polypeptides dirigés contre ou se liant spécifiquement au récepteur de chimiokines CXCR2 et en particulier des polypeptides capables de moduler le signal de transduction provenant de CXCR2. L'invention concerne également des acides nucléiques, des vecteurs et des cellules hôtes capables d'exprimer les polypeptides selon l'invention, des compositions pharmaceutiques comportant les polypeptides et les utilisations desdits polypeptides et compositions pour le traitement de maladies impliquant le fonctionnement aberrant de CXCR2.
MA35963A 2010-11-08 2013-06-05 Polypeptides se liant aux recepteurs de chimiokines MA34711B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41108310P 2010-11-08 2010-11-08
PCT/EP2011/069571 WO2012062713A1 (fr) 2010-11-08 2011-11-07 Polypeptides se liant aux récepteurs de chimiokines

Publications (1)

Publication Number Publication Date
MA34711B1 true MA34711B1 (fr) 2013-12-03

Family

ID=45001722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35963A MA34711B1 (fr) 2010-11-08 2013-06-05 Polypeptides se liant aux recepteurs de chimiokines

Country Status (26)

Country Link
US (3) US8591896B2 (fr)
EP (3) EP3578568A3 (fr)
JP (2) JP5933573B2 (fr)
KR (2) KR101650995B1 (fr)
CN (1) CN103328512B (fr)
AR (1) AR083784A1 (fr)
AU (4) AU2011328246B2 (fr)
BR (1) BR112013011003B1 (fr)
CA (2) CA3239880A1 (fr)
CL (1) CL2013001168A1 (fr)
CO (1) CO6761351A2 (fr)
CR (1) CR20130202A (fr)
CU (1) CU24111B1 (fr)
EA (2) EA202092589A3 (fr)
ES (2) ES2970234T3 (fr)
GT (1) GT201300113A (fr)
IL (1) IL225897B (fr)
MA (1) MA34711B1 (fr)
MX (2) MX343085B (fr)
NZ (1) NZ610075A (fr)
PE (1) PE20140772A1 (fr)
SG (1) SG189981A1 (fr)
TW (2) TWI619811B (fr)
UA (1) UA115027C2 (fr)
UY (1) UY33714A (fr)
WO (1) WO2012062713A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092589A3 (ru) 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014170317A1 (fr) * 2013-04-17 2014-10-23 Morphosys Ag Anticorps ciblant spécifiquement le cxcr2 humain
CN103396482B (zh) * 2013-05-17 2016-08-10 东南大学 一种前白蛋白纳米抗体、其编码序列及应用
WO2015063331A1 (fr) 2013-11-04 2015-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps synthétique à domaine unique
WO2015189162A1 (fr) * 2014-06-09 2015-12-17 Theranyx Anticorps à domaine unique dirigés contre un récepteur à boucle cys et procédés pour les obtenir
TWI793162B (zh) 2016-06-20 2023-02-21 英商克馬伯有限公司 抗體
CN118184777A (zh) * 2017-01-30 2024-06-14 亚力兄制药公司 单价抗备解素抗体及抗体片段
KR102673489B1 (ko) * 2017-02-27 2024-06-07 모나쉬 유니버시티 Cxcr2 항체 및 그의 용도
US20200277378A1 (en) 2017-11-16 2020-09-03 Novartis Ag Combination therapies
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3108071A1 (fr) 2018-08-01 2020-02-06 Cephalon, Inc. Anticorps anti-cxcr2 et leurs utilisations
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3124935A1 (fr) 2019-02-15 2020-08-20 Novartis Ag Derives de 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione et leurs utilisations
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220092859A (ko) * 2019-09-04 2022-07-04 상하이테크 유니버시티 항-cxcr2 항체 및 이의 용도
AU2020410266A1 (en) 2019-12-20 2022-06-30 Novartis Ag Combination of anti TIM-3 antibody MBG453 and anti TGF-beta antibody NIS793, with or without decitabine or the anti PD-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
IL298262A (en) 2020-06-23 2023-01-01 Novartis Ag A dosage regimen that includes derivatives of 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP4188549A1 (fr) 2020-08-03 2023-06-07 Novartis AG Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
US20240068004A1 (en) * 2022-08-15 2024-02-29 Mbrace Therapeutics, Inc. Cell-free methods of producing antibodies to intracellular targets
WO2024133935A1 (fr) 2022-12-23 2024-06-27 Ablynx Nv Excipients de conjugaison protéiques

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
DK0577752T4 (da) 1991-03-29 2007-10-22 Genentech Inc Human PF4A receptorer og deres anvendelse
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5374506A (en) 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
ES2322324T3 (es) 1992-08-21 2009-06-19 Vrije Universiteit Brussel Inmumoglobulinas desprovistas de cadenas ligeras.
EP0702721B1 (fr) 1993-06-09 2001-01-03 Unilever N.V. Procede de production de proteines de fusion comprenant des fragments de scfv a l'aide d'un moule transforme
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
US6448379B1 (en) 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
CA2183667A1 (fr) 1994-02-22 1995-08-24 Wayne A. Marasco Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
EP1027073A2 (fr) 1996-11-19 2000-08-16 Sangstat Medical Corporation Effets renforces pour therapeutique associee a l'haptene
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1027439B1 (fr) 1997-10-27 2010-03-17 Bac Ip B.V. Proteines multivalentes de fixation de l'antigene
CA2321199A1 (fr) 1998-02-19 1999-08-26 William A. Brady Compositions et procedes de regulation de l'activation des lymphocytes
EP0967284A1 (fr) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiestérases
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
NZ513356A (en) 1999-02-05 2004-01-30 Univ Leiden Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate
WO2001077137A1 (fr) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Proteines de fusion d'albumine
CA2367955C (fr) 1999-03-15 2009-05-19 University Of British Columbia Methodes et reactifs permettant de moduler les taux de cholesterol
BR0011753A (pt) 1999-06-18 2002-04-30 Cv Therapeutics Inc Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp
WO2001009300A2 (fr) 1999-08-02 2001-02-08 Keygene N.V. Technique de generation d'une resistance contre le virus de la mosaique marbrure du concombre vert (cgmmv) chez les plantes, constructions genetiques necessaires a cette technique, et plantes resistant au cgmmv obtenues au moyen de ladite technique
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
ATE337403T1 (de) 1999-12-24 2006-09-15 Genentech Inc Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
JP2003530325A (ja) * 2000-03-31 2003-10-14 イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤
WO2002057445A1 (fr) 2000-05-26 2002-07-25 National Research Council Of Canada Anticorps cibles sur le cerveau a domaine unique, derives d'anticorps de lama
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
MXPA03006358A (es) 2001-01-17 2004-12-02 Trubion Pharmaceuticals Inc Proteinas de fusion dominio de enlace-inmunoglobulina.
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US20030017150A1 (en) 2001-03-14 2003-01-23 Torphy Theodore J. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1425694A2 (fr) 2001-08-03 2004-06-09 Medical Research Council Methode pour identifier la sequence consensus pour des anticorps intracellulaires
EP1427829A4 (fr) 2001-08-31 2005-10-12 Abmaxis Inc Conjugues de proteines multivalentes ayant des domaines de liaison de ligand multiples de recepteurs
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
WO2004037999A2 (fr) 2002-10-23 2004-05-06 Ludwig Institute For Cancer Research Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
US20060263774A1 (en) 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004041862A2 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
EP1558650A2 (fr) 2002-11-08 2005-08-03 Ablynx N.V. Procede d'administration de polypeptides therapeutiques et polypeptides associes
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
WO2004051268A1 (fr) 2002-12-03 2004-06-17 Celltech R & D Limited Dosage biologique permettant d'identifier des cellules productrices d'anticorps
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
CA2535550A1 (fr) 2003-08-12 2005-03-03 William M. Yarbrough Traitement de l'acne simple et procede d'utilisation
ES2385829T3 (es) 2003-08-20 2012-08-01 Ucb Pharma, S.A. Métodos para obtener anticuerpos
WO2005103702A2 (fr) 2004-04-20 2005-11-03 Bayer Healthcare Ag Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur 2 de la chimiokine cxc (cxcr2)
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
AU2005263994B2 (en) 2004-07-22 2011-03-24 Roger Kingdon Craig Binding molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
WO2006040154A2 (fr) 2004-10-14 2006-04-20 Dublin City University Systeme procaryote a deux hybrides
NO322440B1 (no) 2004-10-19 2006-10-09 Per-Yngve Monsen Fremgangsmate og datasystem for ervervelse av kunder
EP1844073A1 (fr) 2005-01-31 2007-10-17 Ablynx N.V. Procede de generation de sequences a domaine variable d'anticorps a chaine lourde
EP2479191A3 (fr) * 2005-05-18 2013-03-13 Ablynx N.V. NanobodiesTM améliorés contre le facteur alpha de la nécrose des tumeurs
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
CA2617539A1 (fr) 2005-07-01 2007-01-11 Washington University In St. Louis Anticorps des recepteurs de chimiokines phosphospecifiques
EP2520588A1 (fr) 2005-08-19 2012-11-07 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
WO2007112940A2 (fr) 2006-03-31 2007-10-11 Ablynx N.V. Séquence d'acides aminés dérivée de l'albumine, son utilisation pour augmenter la demi-vie de protéines thérapeutiques et d'autres composés et entités thérapeutiques, et produits de recombinaison qui la comprennent
WO2007118670A1 (fr) 2006-04-14 2007-10-25 Ablynx N.V. Nanocorps de type dp-78
CN101070346A (zh) * 2006-05-08 2007-11-14 陈正贤 一种制备双功能抗体的方法
EP2040995A1 (fr) 2006-06-26 2009-04-01 Aida Centre, S.L. Conditionnement sous blister intégrant des étiquettes rfid
US20130004480A1 (en) 2006-07-04 2013-01-03 Paul Parren CD20 Binding Molecules for the Treatment of Copd
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
US7943310B2 (en) 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
EP2069402A2 (fr) 2006-09-08 2009-06-17 Ablynx N.V. Protéines à demi-vie longue se liant à l'albumine sérique
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008043821A1 (fr) 2006-10-11 2008-04-17 Ablynx N. V. Séquences d'acides aminés se liant à des protéines sériques essentiellement indépendamment du ph, composés les comprenant et utilisations correspondantes
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
JP5373823B2 (ja) 2008-01-29 2013-12-18 アブリンクス エン．ヴェー． タンパク質及びポリペプチドを安定化する方法
NL2001374C2 (nl) 2008-03-13 2009-09-15 Securo B V Werkwijze voor het machinaal vervaardigen van een samenstel van een eerste flexibel vel en een tweede flexibel vel.
CN102099378B (zh) * 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
EP2352764B1 (fr) * 2008-10-14 2018-03-28 Ablynx N.V. Séquences des acides aminés ciblant cd4 et cxcr4, ccr5, tlr4, alphav integrin, beta3-integrin, beta1-integrin, alpha2-integrin humain, cd81, sr-bi, claudin-1, claudin-6 et/ou claudin-9 humain, respectivement, et neutralisant l'entrée virale
EP3470425A3 (fr) * 2008-12-19 2019-07-17 Ablynx N.V. Procédé de génération de séquences d'immunoglobulines
CN102239181A (zh) 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 用于鉴定细胞表面抗原的免疫结合剂的方法
EA202092589A3 (ru) 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды

Also Published As

Publication number Publication date
ES2970234T3 (es) 2024-05-27
EP3575321B1 (fr) 2023-07-26
EP2638068B1 (fr) 2018-12-26
US20140050736A1 (en) 2014-02-20
GT201300113A (es) 2015-06-02
AU2018275016A1 (en) 2019-01-03
CR20130202A (es) 2013-06-28
KR101650995B1 (ko) 2016-08-25
US20170101476A1 (en) 2017-04-13
CA3239880A1 (fr) 2012-05-18
TW201736401A (zh) 2017-10-16
US20120183549A1 (en) 2012-07-19
EA202092589A3 (ru) 2021-06-30
KR20150051245A (ko) 2015-05-11
US9127067B2 (en) 2015-09-08
EP3575321A1 (fr) 2019-12-04
CN103328512A (zh) 2013-09-25
CL2013001168A1 (es) 2014-04-04
CO6761351A2 (es) 2013-09-30
BR112013011003B1 (pt) 2021-12-07
JP2013545456A (ja) 2013-12-26
EA202092589A2 (ru) 2021-03-31
UY33714A (es) 2012-06-29
AU2011328246B2 (en) 2016-06-30
AU2016234907A1 (en) 2016-10-20
IL225897B (en) 2019-03-31
JP6294382B2 (ja) 2018-03-14
JP5933573B2 (ja) 2016-06-15
TW201233795A (en) 2012-08-16
CA2817132A1 (fr) 2012-05-18
TWI619811B (zh) 2018-04-01
MX343085B (es) 2016-10-24
AU2020217351A1 (en) 2020-09-03
AU2011328246A1 (en) 2013-05-23
EA201390666A1 (ru) 2013-11-29
US10174118B2 (en) 2019-01-08
IL225897A0 (en) 2013-06-27
BR112013011003A2 (pt) 2016-08-23
CN103328512B (zh) 2017-04-05
EP2638068A1 (fr) 2013-09-18
UA115027C2 (uk) 2017-09-11
CU20130066A7 (es) 2013-09-27
AU2020217351B2 (en) 2023-08-03
ES2723775T3 (es) 2019-09-02
JP2016174611A (ja) 2016-10-06
AR083784A1 (es) 2013-03-20
SG189981A1 (en) 2013-06-28
WO2012062713A1 (fr) 2012-05-18
CU24111B1 (es) 2015-08-27
EA037063B1 (ru) 2021-02-01
EP3578568A2 (fr) 2019-12-11
KR101832040B1 (ko) 2018-04-04
KR20130108414A (ko) 2013-10-02
AU2018275016B2 (en) 2020-07-09
TWI619730B (zh) 2018-04-01
MX2022013520A (es) 2022-11-16
PE20140772A1 (es) 2014-07-03
NZ610075A (en) 2015-03-27
MX2013005186A (es) 2013-07-03
EP3578568A3 (fr) 2020-01-08
US8591896B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
MA34711B1 (fr) Polypeptides se liant aux recepteurs de chimiokines
WO2008060367A3 (fr) Anticorps humains qui se lient au cxcr4, et leurs utilisations
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA33892B1 (fr) Anticorps anti-her3, et leurs utilisations
EP3199551A3 (fr) Anticorps entièrement humains de btla
MA34209B1 (fr) Protéines à domaine de squelette basé sur la fibronectine qui se lient à pcsk9
MA32948B1 (fr) Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t
EP2826791A3 (fr) Anticorps anti-C5aR humanisés
WO2010002862A3 (fr) Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
WO2006023852A3 (fr) Modulateurs des recepteurs muscariniques
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
WO2010136311A3 (fr) Compositions et procédés de ciblage de la protéine c3b de complément par des anticorps
MA33815B1 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
MA32892B1 (fr) Anticorps anti-cmet
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
EA201001223A1 (ru) Стабилизированные белковые композиции
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
WO2006058294A3 (fr) Modulateurs des recepteurs muscariniques
MA44922B1 (fr) Anticorps
WO2007100664A3 (fr) Modulateurs des récepteurs muscariniques
WO2005101838A3 (fr) Utilisation de derives de piperazinylpiperidine comme antagonistes de recepteurs de chimiokines
WO2008079352A3 (fr) Anticorps dirigés contre cd200r
WO2009139853A3 (fr) Anticorps monoclonaux humains dirigés contre le récepteur de chimiokines humaines ccr7